Clin2
NCT04746183Possibly a fitRecruiting

Early trial testing treatments for COVID-19 in the first days

Covid19

Treatments studied

Part of Infections, Lungs & breathing clinical trials.

This early-stage study tests COVID-19 treatments in people who have recently developed symptoms and who test positive for the virus. It aims to find safer, more effective options for preventing worsening disease, especially in higher-risk groups.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
600 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You’re an adult (age 18 or older) with confirmed COVID-19 by a lab test (PCR) or, in some parts of the study, a rapid test (lateral flow).
  • You can sign consent yourself (or have a legal representative sign).
  • You must not be pregnant or breast-feeding.
  • If you can become pregnant, or you’re a man with a partner who can become pregnant, you must use reliable birth control exactly as the study requires during treatment and afterward.
  • Your COVID-19 symptoms must have started within a short time window before the first dose (often within 5 days, depending on the group).
  • You must be able to follow study visits and procedures for the first several weeks.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04896606Recruiting· Phase 1/Phase 2
Matched donor immune therapy for mild to moderate COVID-19

This early-phase study tests immune cells from a matched family donor (made to target the COVID-19 virus) to see if they can help people with mild-to-moderate COVID-19 who are hospitalized and at higher risk for getting sicker. It aims to check safety first and also look for signs of benefit.

Valhalla, New York
NCT05041907Recruiting· Phase 2
Testing an antiviral’s effects in early COVID-19

This trial looks at how well an antiviral works in the body when started early in people with COVID-19 symptoms. You may be able to join if you’re an otherwise healthy adult with confirmed infection and symptoms for less than 4 days.

Minas Gerais
NCT04709328Not yet recruiting· Phase 2/Phase 3
SCT A01 for high-risk outpatients with early COVID-19

This trial tests SCTA01 (or a placebo) in people who are not hospitalized but have early COVID-19 symptoms and higher risk of getting very sick. It may help prevent worsening illness by acting soon after infection.

NCT05218356Recruiting· Phase 2
Codivir trial for hospitalized moderate COVID-19

This trial tests whether Codivir can help people hospitalized with moderate COVID-19 recover better than a placebo (inactive pill). It will compare outcomes while participants receive standard hospital care.

Paulo Prata, Barretos/SP/BRA
NCT05261139Recruiting· Phase 3
Trial for PF-07321332 for children at risk from COVID-19

This trial studies whether PF-07321332 (with ritonavir) helps children under 18 who have COVID-19 at home but are at high risk of severe illness. It looks at whether starting treatment early can reduce progression to worse disease.

Phoenix, Arizona
NCT07157007Recruiting· Phase 2
Testing a New COVID-19 Drug for Mild to Moderate Cases

This trial tests a new drug, ratutrelvir, for people with mild to moderate COVID-19. It aims to find a safe and effective dose to help you feel better faster.

Charlestown, New South Wales

Hear when a new Covid19 trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.